Ken Griffin Corcept Therapeutics Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 185,900 shares of CORT stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,900

Previous 276,500 32.77%

Holding current value

$10.7 Million

Previous $6.97 Million 13.3%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$22.21 - $34.48 $103,520 - $160,711	-4,661 Reduced 1.76%	259,648 $8.44 Million
Q1 2024 May 15, 2024	SELL	$21.1 - $27.46 $3.75 Million - $4.88 Million	-177,650 Reduced 40.2%	264,309 $6.66 Million
Q4 2023 Feb 14, 2024	BUY	$24.82 - $32.88 $2.79 Million - $3.7 Million	112,510 Added 34.15%	441,959 $14.4 Million
Q3 2023 Nov 14, 2023	SELL	$21.97 - $33.8 $1.61 Million - $2.48 Million	-73,496 Reduced 18.24%	329,449 $8.98 Million
Q2 2023 Aug 14, 2023	BUY	$21.44 - $25.15 $4.82 Million - $5.66 Million	224,886 Added 126.3%	402,945 $8.97 Million
Q1 2023 May 15, 2023	SELL	$19.2 - $24.47 $63,110 - $80,432	-3,287 Reduced 1.81%	178,059 $3.86 Million
Q4 2022 Feb 14, 2023	SELL	$19.95 - $29.96 $2.66 Million - $4 Million	-133,414 Reduced 42.39%	181,346 $3.68 Million
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $2.74 Million - $3.24 Million	111,093 Added 54.55%	314,760 $8.07 Million
Q2 2022 Aug 15, 2022	SELL	$17.33 - $25.3 $131,118 - $191,419	-7,566 Reduced 3.58%	203,667 $4.84 Million
Q1 2022 May 16, 2022	BUY	$16.53 - $25.21 $3.16 Million - $4.82 Million	191,315 Added 960.51%	211,233 $4.76 Million
Q2 2021 Aug 16, 2021	SELL	$19.97 - $24.43 $1.47 Million - $1.8 Million	-73,743 Reduced 78.73%	19,918 $438,000
Q1 2021 May 17, 2021	SELL	$23.49 - $30.56 $2.11 Million - $2.75 Million	-89,925 Reduced 48.98%	93,661 $2.23 Million
Q4 2020 Feb 16, 2021	BUY	$16.78 - $27.3 $1.51 Million - $2.46 Million	90,157 Added 96.5%	183,586 $4.8 Million
Q3 2020 Nov 16, 2020	SELL	$12.46 - $19.98 $1.76 Million - $2.82 Million	-141,249 Reduced 60.19%	93,429 $1.63 Million
Q2 2020 Aug 14, 2020	SELL	$11.0 - $18.26 $3.21 Million - $5.33 Million	-291,717 Reduced 55.42%	234,678 $3.95 Million
Q1 2020 May 15, 2020	SELL	$10.11 - $14.04 $4.84 Million - $6.72 Million	-478,663 Reduced 47.63%	526,395 $6.26 Million
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $3.54 Million - $4.97 Million	293,305 Added 41.21%	1,005,058 $12.2 Million
Q3 2019 Nov 14, 2019	SELL	$10.41 - $14.66 $3.11 Million - $4.38 Million	-298,713 Reduced 29.56%	711,753 $10.1 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $12.76 $8.4 Million - $11 Million	859,000 Added 567.12%	1,010,466 $11.3 Million
Q1 2019 May 15, 2019	SELL	$10.03 - $15.71 $1.27 Million - $1.99 Million	-126,388 Reduced 45.49%	151,466 $0
Q4 2018 Feb 14, 2019	BUY	$11.29 - $17.19 $2.93 Million - $4.46 Million	259,260 Added 1394.32%	277,854 $3.71 Million
Q3 2018 Nov 13, 2018	SELL	$12.27 - $15.65 $42,822 - $54,618	-3,490 Reduced 15.8%	18,594 $0
Q2 2018 Aug 10, 2018	SELL	$15.3 - $19.69 $3.23 Million - $4.16 Million	-211,165 Reduced 90.53%	22,084 $0
Q1 2018 May 11, 2018	BUY	$14.59 - $25.5 $2.88 Million - $5.04 Million	197,673 Added 555.64%	233,249 $3.84 Million
Q4 2017 Feb 09, 2018	SELL	$15.77 - $20.72 $1.52 Million - $1.99 Million	-96,260 Reduced 73.01%	35,576 $643,000
Q3 2017 Nov 09, 2017	BUY	$12.3 - $19.3 $1.62 Million - $2.54 Million	131,836	131,836 $2.54 Million

Others Institutions Holding CORT

# of Institutions

337

Shares Held

87.5M

Call Options Held

1.08M

Put Options Held

852K

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.19B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account